Overall MYOV gets a fundamental rating of 2 out of 10. We evaluated MYOV against 525 industry peers in the Biotechnology industry. Both the profitability and financial health of MYOV have multiple concerns. MYOV is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

MYOV had negative earnings in the past year.
In the past year MYOV has reported a negative cash flow from operations.

1.2 Ratios

The profitability ratios for MYOV are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 73.03%, MYOV belongs to the top of the industry, outperforming 84.43% of the companies in the same industry.
MYOV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	73.03%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MYOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
MYOV has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, MYOV has a worse debt to assets ratio.

2.2 Solvency

MYOV has an Altman-Z score of -2.98. This is a bad value and indicates that MYOV is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MYOV (-2.98) is worse than 60.53% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-2.98

ROIC/WACCN/A

WACC7.64%

2.3 Liquidity

MYOV has a Current Ratio of 1.57. This is a normal value and indicates that MYOV is financially healthy and should not expect problems in meeting its short term obligations.
MYOV's Current ratio of 1.57 is on the low side compared to the rest of the industry. MYOV is outperformed by 84.43% of its industry peers.
MYOV has a Quick Ratio of 1.45. This is a normal value and indicates that MYOV is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.45, MYOV is not doing good in the industry: 83.96% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.57
Quick Ratio	1.45

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MYOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.67%, which is quite impressive.
Looking at the last year, MYOV shows a very strong growth in Revenue. The Revenue has grown by 91.46%.

EPS 1Y (TTM)22.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%13.24%

Revenue 1Y (TTM)91.46%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%84.11%

3.2 Future

MYOV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.08% yearly.
The Revenue is expected to grow by 45.18% on average over the next years. This is a very strong growth

EPS Next Y19.42%

EPS Next 2Y25.59%

EPS Next 3Y20.67%

EPS Next 5Y25.08%

Revenue Next Year81.1%

Revenue Next 2Y53.4%

Revenue Next 3Y43.72%

Revenue Next 5Y45.18%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MYOV. In the last year negative earnings were reported.
Also next year MYOV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.